Peripherally inserted central catheter-related bloodstream infections in patients with hematological malignancies: A retrospective 7-years single-center study

ObjectivesWe sought to investigate the nature and incidence of bloodstream infection complications and to identify the risk factors of central catheter-related bloodstream infections (CRBSI).MethodsDuring the study period, 291 consecutive patients with hematological malignancies who underwent PICC placement were retrospectively enrolled. We analyzed the covariates that were specified a priori for their association with CRBSI through multivariate Cox proportional hazards regression models. The association between each predictor and the related outcome was expressed using hazard ratios (HRs) with corresponding 95% confidence intervals (CIs).ResultsOf 391 peripherally inserted central catheter (PICCs) were inserted in 291 patients for a total of 63,714 catheter days during 7 years, with an infection rate of 0.71/1,000 catheter days. Among the patients with hematological malignancies, those with acute leukemia were prone to CRBSI. Having previous bloodstream infection (BSI) (HR 18.139; 95% CI, 8.19-40.174; P < .0001), the number of PICCs insertions (HR 4.695; 95% CI, 1.842-11.967; P = .001) (twice), (HR 6.794; 95% CI, 1.909-24.181; P = .003) (≥3 times) were significantly associated with CRBSI. Not accompanied by chronic comorbidities (HR 0.34; 95% CI, 0.131-0.887; P = .028) and longer duration of PICC use (days) (HR 0.997; 95% CI, 0.994-0.999; P = .008) might be protective factors preventing CRBSI.ConclusionsOur finding suggests that previous BSI and a higher number of PICC insertions are associated with an increased risk of CRBSI. A lack of chronic comorbidities may help prevent CRBSI.     

Clinical efficacy and safety of Shuxuetong injection for acute myocardial infarction: A protocol for systematic review and meta-analysis

Background:Shuxuetong injection (SXT) is a Chinese medicine injection and has been widely used for the treatment of acute myocardial infarction (AMI) in Asia. However, whether SXT has a definite efficacy and safety is poorly understood. The aim of our study was to clarify the effect of SXT on clinical symptoms alliavation and survival in AMI patients.Methods:A systematic reviews of SXT combined with conventional therapy treating AMI will be searched in 8 electronic databases including PubMed, Cochrane Library, Embase, Wanfang Database, China Biology Medicine (CBM), Google Scholar, Chinese Scientific Journal Database (VIP), and China National Knowledge Infrastructure (CNKI), from inception to December 2020. The literature will extracted by 2 researchers independently and the methodological quality of the included study will be evaluated. We will use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to evaluate the evidence quality of the included literature. RevMan software (version 5.3) will be applied for the original research data synthesis.Results:The results of our study will be published in a peer reviewed journal.Conclusion:Our meta-analysis will provide the latest evidence to determine whether SXT is an effective intervention for AMI patients.     

Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study

Clinical Rheumatology - The equivalence of the biosimilar HS016 to adalimumab (Humira) for the treatment of active ankylosing spondylitis (AS) patients has been previously validated. The aim was to...     

Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center,randomized, double-blind,phase III clinical trial

Clinical Rheumatology - To assess the clinical equivalence of TQ-Z2301, a biosimilar of adalimumab, to the reference adalimumab in the treatment of Chinese patients with active ankylosing...     

Implantable vaccine development using in vitro antigen-pulsed macrophages absorbed on laser micro-structured Si scaffolds

To overcome the limiting antigenic repertoire of protein sub-units and the side effects of adjuvants applied in second generation vaccines, the present work combined in vitro and in vivo manipulations to develop biomaterials allowing natural antigen-loading and presentation in vitro and further activation of the immune response in vivo. 3-dimensional laser micro-textured implantable Si-scaffolds supported mouse macrophage adherence, allowed natural seeding with human serum albumin (antigen) and specific antibody and inflammatory cytokine production in vitro. Implantation of Si-scaffolds loaded with antigen-activated macrophages induced an inflammatory reaction along with antigen-specific antibody production in vivo, which could be detected even 30 days post implantation. Analysis of implant histology using scanning electron microscopy showed that Si-scaffolds could be stable for a 6-month period. Such technology leads to personalized implantable vaccines, opening novel areas of research and treatment.     

五红汤对化疗后小鼠外周血细胞及骨髓造血祖细胞的影响

目的:探讨食疗五红汤(枸杞子、红豆、红衣花生、红糖、红枣)对小鼠化疗后骨髓抑制的治疗作用,并初步探讨其可能的作用机制。方法:昆明种小鼠64只随机分为4组(化疗组、化疗+五红汤组、五红汤组、空白组),采用腹腔注射环磷酰胺(CTX)方法进行化疗后骨髓抑制造模,造模后分别给予五红汤及生理盐水灌胃;五红汤组及空白对照组小鼠予腹腔注射生理盐水后分别给予五红汤及生理盐水灌胃,观察干预后小鼠外周血白细胞(WBC)、红细胞(RBC)、血小板(PLT)的变化及骨髓红系祖细胞(BFU-E)、粒单细胞集落形成细胞(CFU-GM)和有核细胞计数以及CD34+细胞凋亡情况。结果:用药前各组小鼠外周血细胞(WBC、RBC、PLT)差异均无统计学意义;用药8 d后,化疗+五红汤组小鼠的WBC计数、PLT计数均明显高于单纯化疗组(P0.05,P0.01),而各组间RBC计数差异无统计学意义;4组小鼠骨髓BFU-E、CFUGM、CD34+表达率之间差异均无统计学意义(P0.05)。结论:五红汤对CTX化疗后骨髓抑制模型小鼠的白细胞、血小板有较显著的提高作用,但对红细胞及小鼠骨髓造血祖细胞影响均不明显,对正常小鼠外周血细胞亦无影响。     

序贯疗法与标准三联疗法治疗幽门螺杆菌感染的随机对照试验

【目的】观察疗程10 d序贯治疗以及14 d中西医结合序贯治疗与14 d标准三联疗法作为幽门螺杆菌(Hp)感染一线治疗方案的有效性。【方法】将90例年龄在18岁及以上的Hp感染者,按1︰1︰1比例随机分为10 d序贯方案组(S-10组)、14 d中西医结合序贯方案组(S-14组)以及14 d标准三联方案组(T-14组)各30例。序贯方案组选择最初7 d(或者5 d)口服埃索美拉唑20 mg及阿莫西林1.0 g,序贯7 d(或者5 d)服用埃索美拉唑20 mg及克拉霉素500 mg、甲硝唑500 mg,S-10组与S-14组的疗程分别为10 d和14 d,其中S-14组同时给予辨证服用中药汤剂;T-14组选择口服埃索美拉唑20 mg,阿莫西林1.0 g及克拉霉素500 mg,疗程为14 d。观察各组患者的Hp根除率、不良事件发生率以及患者的依从性,并对可能影响根除率的因素进行分析。【结果】(1)S-14、S-10、T-14组的根除率分别为90.0%、86.7%、83.3%,S-14组的根除率显著高于T-14组(P﹤0.05),而S-14组与S-10组,S-10组与T-14组之间的治疗结局比较,差异均无统计学意义(P>0.05)。(2)3组之间不良反应的发生率和患者依从性比较,差异均无统计学意义(P>0.05)。(3)影响根除率的因素分析结果显示:克拉霉素的耐药性会降低序贯疗法和三联标准疗法的有效性,而甲硝唑的耐药性会降低序贯疗法的有效性。【结论】本次临床试验结果支持将序贯治疗作为抗Hp感染的一线治疗方案。     

中药外敷加灌肠治疗阑尾周围脓肿的疗效及其对C-反应蛋白的影响

【目的】观察中药双柏散外敷配合通腑泻热合剂灌肠治疗阑尾周围脓肿的临床疗效及其对血清中C-反应蛋白(CRP)含量的影响。【方法】将60例阑尾周围脓肿患者随机分为对照组和治疗组各30例,对照组给予常规西药治疗,治疗组在对照组治疗的基础上加用双柏散外敷及通腑泻热合剂保留灌肠,7 d为1个疗程,2个疗程后观察2组患者的临床疗效及血清CRP的变化情况。【结果】(1)治疗组总有效率为93.33%,对照组为73.33%,治疗组疗效优于对照组(P<0.05)。(2)治疗后,治疗组的体温恢复正常时间及腹痛消失时间均较对照组显著缩短(P<0.05),包块较对照组显著缩小(P<0.01)。(3)治疗后,2组血清CRP含量均显著下降(P<0.01),但治疗组的下降作用更明显(P<0.05)。【结论】在常规西药治疗的基础上配合双柏散外敷及通腑泻热合剂灌肠治疗阑尾周围脓肿,不仅能有效改善患者临床症状,还能降低患者血清CRP水平,疗效肯定,且无明显毒副作用,值得临床推广应用。     

Association of expression of ZNF606 gene from monocytes with the risk of coronary artery disease

AimMessenger RNAs (mRNAs) play an important role in the pathogenesis of coronary artery disease (CAD). We evaluated the association of selected increase in mRNAs from monocytes with the risk of CAD.MethodsChip data (GSE9820) retrieved from Gene Expression Omnibus (GEO) was re-analyzed, and the selected candidate genes, meeting specific conditions, were up-regulated and verified for specific biomarkers of CAD within a prospective cohort study that recruited 194 individuals and subdivided into two groups: group Non-CAD (GN), n = 68 and group CAD (GC), n = 126. The patients in GC were further categorized into three sub-units according to the extent of coronary stenosis shown during coronary angiography, coded as single-vessel stenosis (GC1, n = 53), 2-vessel stenosis (GC2, n = 50), or ≥ 3-vessel stenosis (GC3, n = 23). All candidate mRNAs expressions were analyzed from patients' monocytes with quantitative PCR (q-PCR). Receiver-operating characteristic (ROC) curves and the area under the ROC curves (AUCs) were used to evaluate the mRNAs' feasibility for CAD prediction. AUCs ≥0.8 were accounted as highly specific association with CAD.ResultsGBA2, CSTF3, ZNF606 and MPP5 were selected as mRNAs candidates from chip data reanalysis. GBA2 (P = .002) and ZNF606 (P < .001) expressions were significantly increased in GC. ZNF606 showed significant increase after adjusting the risk factors with logistic regression analysis (OR = 3.804, 95% CI: 1.923, 7.798, P < .001), and its expression level was positively correlated with age (β = 0.04 × 10⁻³, P < .001). The AUCs (and 95% CI) of ZNF606 expression in GC2 and GC3 were ≥0.8.ConclusionThese findings suggest that it is novel and specific for the association of ZNF606 gene expression from monocytes with the risk of CAD, especially in patients with multiple coronary artery stenosis.